Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptorum Group Limited stock logo
APM
Aptorum Group
$1.39
-4.8%
$1.26
$0.46
$7.49
$7.81M-0.1252,620 shs52,096 shs
CI Canadian Convertible Bond ETF Common stock logo
CXF
CI Canadian Convertible Bond ETF Common
C$10.27
-0.7%
C$10.28
C$9.72
C$10.57
C$51.91MN/A4,229 shs1,674 shs
Gear Energy Ltd. stock logo
GXE
Gear Energy
C$0.50
C$0.45
C$0.80
C$126.52M3.52585,822 shs1.03 million shs
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$2.00
-1.0%
$1.49
$0.27
$2.41
$93.23M0.491.30 million shs767,654 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptorum Group Limited stock logo
APM
Aptorum Group
-4.79%+10.32%-28.35%+45.99%-57.62%
CI Canadian Convertible Bond ETF Common stock logo
CXF
CI Canadian Convertible Bond ETF Common
-0.68%-0.29%+0.59%+2.39%+3.95%
Gear Energy Ltd. stock logo
GXE
Gear Energy
0.00%0.00%0.00%0.00%-31.43%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-0.99%0.00%+3.63%+304.20%+194.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptorum Group Limited stock logo
APM
Aptorum Group
0.6977 of 5 stars
0.02.00.00.02.51.70.6
CI Canadian Convertible Bond ETF Common stock logo
CXF
CI Canadian Convertible Bond ETF Common
N/AN/AN/AN/AN/AN/AN/AN/A
Gear Energy Ltd. stock logo
GXE
Gear Energy
N/AN/AN/AN/AN/AN/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
2.2862 of 5 stars
3.53.00.00.02.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00
N/AN/AN/A
CI Canadian Convertible Bond ETF Common stock logo
CXF
CI Canadian Convertible Bond ETF Common
0.00
N/AN/AN/A
Gear Energy Ltd. stock logo
GXE
Gear Energy
2.00
HoldN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
3.00
Buy$4.00100.00% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptorum Group Limited stock logo
APM
Aptorum Group
$430K17.29N/AN/A$2.20 per share0.63
CI Canadian Convertible Bond ETF Common stock logo
CXF
CI Canadian Convertible Bond ETF Common
N/AN/AN/AN/AN/AN/A
Gear Energy Ltd. stock logo
GXE
Gear Energy
C$134.93M0.00N/A540.00C$0.93 per share0.00
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$17.59M5.25N/AN/A$0.37 per share5.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptorum Group Limited stock logo
APM
Aptorum Group
-$4.27MN/A0.00N/AN/AN/AN/AN/A
CI Canadian Convertible Bond ETF Common stock logo
CXF
CI Canadian Convertible Bond ETF Common
N/AN/A0.00N/AN/AN/AN/AN/A
Gear Energy Ltd. stock logo
GXE
Gear Energy
C$13.02MC$0.0510.39N/AN/A8.53%5.08%4.84%N/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%9/15/2025 (Estimated)

Latest CXF, IPA, APM, and GXE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q4 2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$0.02-$0.04-$0.02-$0.04$7.89 million$5.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/AN/A
CI Canadian Convertible Bond ETF Common stock logo
CXF
CI Canadian Convertible Bond ETF Common
C$0.484.67%N/AN/AN/A
Gear Energy Ltd. stock logo
GXE
Gear Energy
C$0.0611.46%N/A120.00%N/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptorum Group Limited stock logo
APM
Aptorum Group
N/A
0.22
0.22
CI Canadian Convertible Bond ETF Common stock logo
CXF
CI Canadian Convertible Bond ETF Common
N/AN/AN/A
Gear Energy Ltd. stock logo
GXE
Gear Energy
6.27
1.20
0.56
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.49
2.08
1.85
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptorum Group Limited stock logo
APM
Aptorum Group
305.35 million1.93 millionNot Optionable
CI Canadian Convertible Bond ETF Common stock logo
CXF
CI Canadian Convertible Bond ETF Common
905.05 millionN/ANot Optionable
Gear Energy Ltd. stock logo
GXE
Gear Energy
1,310263.58 millionN/ANot Optionable
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
8046.15 million43.00 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aptorum Group stock logo

Aptorum Group NASDAQ:APM

$1.39 -0.07 (-4.79%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$1.40 +0.01 (+0.72%)
As of 08/15/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

CI Canadian Convertible Bond ETF Common stock logo

CI Canadian Convertible Bond ETF Common TSE:CXF

C$10.27 -0.07 (-0.68%)
As of 08/15/2025 12:59 PM Eastern

The investment objectives of First Asset Canadian Convertible Bond ETF are to provide holders with (i) quarterly cash distributions, and (ii) the opportunity for capital appreciation by investing on a capitalization weighted basis in a portfolio (the Convertible Portfolio) of Convertible Bonds of Canadian issuers. The Convertible ETF will invest on a capitalization weighted basis in Convertible Bonds which meet the Eligibility Criteria. Capitalization weightings are determined on the basis of a Convertible Bonds relative market capitalization to the total market capitalization of Convertible Bonds included in the Convertible Portfolio, on initial investment and on quarterly rebalancings.

Gear Energy stock logo

Gear Energy TSE:GXE

Gear Energy Ltd., an exploration and production company, engages in the acquiring, developing, and holding of interests in petroleum and natural gas properties and assets in Canada. The company's oil properties are located in Central Alberta, West Central Saskatchewan, and Southeast Saskatchewan. Gear Energy Ltd. is headquartered in Calgary, Canada.

ImmunoPrecise Antibodies stock logo

ImmunoPrecise Antibodies NASDAQ:IPA

$2.00 -0.02 (-0.99%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$2.02 +0.02 (+1.00%)
As of 08/15/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.